Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between <i>IL1B</i> rs16944 polymorphism and the risk of idiopathic inflammatory myopathies.

Frontiers in immunology·2026
Same author

Renal efficacy of calcineurin inhibitors in treatment-resistant lupus nephritis: An experience among Mexican patients from a tertiary referral center.

Lupus·2026
Same author

Factors Associated With Delay in the Diagnosis and Treatment of Systemic Lupus Erythematosus: A Qualitative Study With Mexican Patients and Rheumatologists.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2025
Same author

Differential glomerular expression patterns of Th17-related cytokines in Mexican patients with lupus nephritis.

Lupus·2025
Same author

Clinical Practice Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus: 2024 Update.

Reumatologia clinica·2024
Same author

Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023.

Reumatologia clinica·2024
Same journal

Clinical validation of video DASH for upper limb disorders in rheumatic patients.

Reumatologia clinica·2026
Same journal

Coexistence of systemic lupus erythematosus and sarcoidosis: A case-based review.

Reumatologia clinica·2026
Same journal

Factors associated with the perception of body image in patients with psoriatic disease.

Reumatologia clinica·2026
Same journal

Anti-Mi-2-positive amyopathic dermatomyositis unveiled by a V-sign.

Reumatologia clinica·2026
Same journal

Antinuclear antibody detection beyond anti-dsDNA and anti-ENA: New insights from intact HEp-2 nucleus ELISA.

Reumatologia clinica·2026
Same journal

Long-term stability of autoantibody-based serological profiles in systemic lupus erythematosus.

Reumatologia clinica·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

[Myopathies and malignancy].

Lilia Andrade-Ortega1

  • 1Servicio de Reumatología, Centro Médico Nacional 20 de Noviembre, ISSSTE, México D. F., México; Universidad Nacional Autónoma de México, México D. F., México. liliaandrade@prodigy.net.mx

Reumatologia Clinica
|July 29, 2011
PubMed
Summary
This summary is machine-generated.

Patients with inflammatory myositis, particularly dermatomyositis, face an elevated risk of developing cancer. This chapter details the clinical and serological features, common cancers, and diagnostic approaches for myositis-cancer patients.

Related Experiment Videos

Last Updated: May 30, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Area of Science:

  • Rheumatology
  • Oncology
  • Dermatology

Context:

  • Inflammatory myositis, especially dermatomyositis, is associated with an increased risk of malignancy.
  • The link between myositis and cancer has been recognized since 1916 and supported by population studies.
  • Understanding this association is crucial for early cancer detection in myositis patients.

Purpose:

  • To describe the clinical and serological characteristics of patients with co-occurring myositis and cancer.
  • To identify the most common malignancies associated with inflammatory myositis.
  • To outline diagnostic and prognostic considerations for this patient cohort.

Summary:

  • Patients with inflammatory myositis, particularly dermatomyositis, exhibit a higher incidence of cancer.
  • Key clinical features, serological markers, and common cancer types in this population are discussed.
  • The chapter provides insights into diagnostic strategies and prognostic factors relevant to myositis-cancer patients.

Impact:

  • Enhances understanding of the paraneoplastic syndromes associated with inflammatory myositis.
  • Aids clinicians in risk stratification and timely cancer screening for myositis patients.
  • Improves diagnostic accuracy and patient outcomes through informed management strategies.